GENE ONLINE|News &
Opinion
Blog

2022-04-18| COVID-19

WHO report highlights the role of Traditional Chinese Medicine in the treatment of COVID-19

by GeneOnline
Share To

BEIJING, April 18, 2022 /PRNewswire/ — A news report by haiwainet.cn:

On March 31, World Health Organization released the meeting report of “WHO Expert Meeting on Evaluation of Traditional Chinese Medicine (TCM) in the Treatment of COVID-19” on its official website. The report acknowledged that on the basis of clinically relevant outcome measures, the studied TCMs are beneficial in the treatment of COVID-19, particularly in mild-to-moderate cases. WHO encourages Member States to consider the integration of traditional medicine interventions such as TCM in planning for the clinical management of COVID-19 in the context of their healthcare systems and regulatory frameworks.

The report pointed out that in the process of treating COVID-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe COVID-19. When administered as add-on interventions to conventional treatment, TCM may shorten the time for viral clearance, resolution of clinical symptoms, and length of hospital stay when compared to conventional treatment alone.

The report recommends that WHO should share the outcomes of this consultation with Member States in a timely manner given the evolving nature of COVID-19 globally. Member States are encouraged to consider the potential use of TCM for the management of COVID-19 in the context of their healthcare systems and regulatory frameworks; share experiences and lessons, particularly those actively acquired through this organized research programme in TCM and clinical experience from China.

Yu Wenming, head of China’s National Administration of Traditional Chinese Medicine, said China is willing to assist other WHO Member States to strengthen the role of traditional medicine in their health systems.

As of March 2022, the Chinese Clinical Trials Registry, which is part of WHO’s ICTRP (International Clinical Trials Registry Platform), showed 859 clinical studies of COVID-19 in China. Among these Chinese clinical trials, 213 relate to TCM.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Lunit AI Solutions to Power Samsung’s X-ray Devices for Advanced Chest Screening
2024-01-16
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
2023-12-24
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-17
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top